Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration

J Vasc Interv Radiol. 2012 Jul;23(7):949-52. doi: 10.1016/j.jvir.2012.04.007.


Sorafenib, a protein kinase inhibitor, is a systemic drug that has been licensed for the treatment of hepatocellular carcinoma (HCC). This retrospective study assessed whether the administration of sorafenib can result in a reduction of the hepatopulmonary shunt (HPS) before selective internal radiation therapy (SIRT). After exclusion from SIRT because of high HPS, computed tomography scan indicated a shunt reduction in seven patients with HCC receiving sorafenib. Repeated measurements revealed HPS reduction (from 26.5% to 7.5% on average), and subsequent SIRT became possible. In conclusion, sorafenib may reduce HPS in patients with advanced HCC in some cases.

Publication types

  • Clinical Trial

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / diagnostic imaging*
  • Carcinoma, Hepatocellular / therapy*
  • Female
  • Hepatopulmonary Syndrome / diagnostic imaging*
  • Hepatopulmonary Syndrome / etiology
  • Hepatopulmonary Syndrome / prevention & control*
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / diagnostic imaging*
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use*
  • Radiography
  • Radiotherapy, Adjuvant
  • Sorafenib
  • Treatment Outcome


  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib